Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9H488

UPID:
OFUT1_HUMAN

ALTERNATIVE NAMES:
Peptide-O-fucosyltransferase 1

ALTERNATIVE UPACC:
Q9H488; A8K4R8; E1P5M4; Q14685; Q5W185; Q9BW76

BACKGROUND:
The enzyme GDP-fucose protein O-fucosyltransferase 1, alternatively known as Peptide-O-fucosyltransferase 1, is integral to the fucosylation of EGF domains, affecting NOTCH signaling and AGRN-mediated acetylcholine receptor clustering. Its specific action of attaching fucose to serine or threonine residues within EGF domains underlines its critical role in cellular communication and development.

THERAPEUTIC SIGNIFICANCE:
Linked to Dowling-Degos disease 2, GDP-fucose protein O-fucosyltransferase 1's dysfunction illustrates its potential as a therapeutic target. The disease's progression and symptoms highlight the need for innovative treatments, making the study of this protein's function and mechanisms a promising avenue for drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.